-

MindMed to Participate in June Conferences

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences:

  • BIO International Convention 2024
    • Panel Name: Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation
    • Date and Time: Tuesday, June 4, 2024 at 4:15 pm PDT
    • Location: San Diego, CA
  • Jefferies 2024 Global Healthcare Conference
    • Format: 1x1 investor meetings only
    • Dates: June 5-6, 2024
    • Location: New York, NY

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.

Contacts

For Media: media@mindmed.co
For Investors: ir@mindmed.co

Industry:

Mind Medicine Inc.

NASDAQ:MNMD
Release Versions
English
$Cashtags
$MNMD

Contacts

For Media: media@mindmed.co
For Investors: ir@mindmed.co

Social Media Profiles
MindMed LinkedIn
MindMed X
More News From Mind Medicine Inc.

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 18,375,000 common shares, without par value, at a public offering price of $12.25 per common share. The gross proceeds to MindMed from the offering, before deducting underwriting discounts, commissions, and other of...

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. In addition, MindMed intends to grant the underwriters an option for a period...

MindMed Announces New Employee Inducement Grant

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to one newly hired non-executive employee consisting of an option to purchase 28,000 common shares of the Company (the "Option") with an effective grant date of October 14, 2025. The Option has an exercise price equal to the closin...
Back to Newsroom